These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22687270)

  • 1. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
    Pantaleo MA; Mandrioli A; Saponara M; Nannini M; Erente G; Lolli C; Biasco G
    BMC Cancer; 2012 Jun; 12():231. PubMed ID: 22687270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
    J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    Di Fiore F; Rigal O; Ménager C; Michel P; Pfister C
    Br J Cancer; 2011 Dec; 105(12):1811-3. PubMed ID: 22095228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
    N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of variant angina in a patient under chronic treatment with sorafenib.
    Porto I; Leo A; Miele L; Pompili M; Landolfi R; Crea F
    Nat Rev Clin Oncol; 2010 Aug; 7(8):476-80. PubMed ID: 20479781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-associated multivessel coronary artery vasospasm.
    Naib T; Steingart RM; Chen CL
    Herz; 2011 Jun; 36(4):348-51. PubMed ID: 21584715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Squamous cell carcinoma in a patient receiving sorafenib].
    Adnot-Desanlis L; Bernard P; Reguiaï Z
    Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
    Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
    Sibaud V; Delord JP; Chevreau C
    Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.